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The term acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute myocardial 
ischemia and includes unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). 
These high-risk manifestations of coronary atherosclerosis are important causes of the use of emergency medical care and hospitalization. High-risk patients with 
UA/NSTEMI are often treated with an early invasive strategy involving cardiac catheterization and prompt revascularization of viable myocardium at risk. Transradial 
approach has important impact in reduction of bleeding and vascular complications. We evaluated the feasibility and the acute performance of the everolimus-eluting 
bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ACS. Methods and results: The present investigation was a prospective, single-
centre study, reporting data after BVS implantation in patients presenting with ACS. Clinical outcomes were reported at the 30-day, 6-month, 1 year and 2 years follow-
up. Quantitative coronary angiography and optical coherence tomography (OCT) data were also evaluated. The intent-to-treat population comprises a total of 21 patients. 
The procedural success was 100.0%. In  14 patients (66.7%) BVS were implanted on left anterior descending artery (LAD), 4 patients (19.0%) on right coronary artery 
(RCA), 3 patients (14.3%) on circumflex artery (Cx). Pre-procedure TIMI-flow was 0 in 8 patients (38.1%). After the BVS implantation a TIMI flow 3 was achieved in 
all 21 patients and the post-procedure percentage diameter stenosis was 16.7 +/- 8.9%. No patients had angiographically visible residual thrombus at the end of the 
procedure. OCT analysis was performed in 13 patients (61.9%) showed that the post-procedure mean lumen area was 7.88 +/- 1.84 mm2, minimum lumen area 5.52 +/- 
1.59 mm2. At the 30-day, 6-month, 1 year (15 patients) and 2 years follow-up (8 patients) target-lesion failure rate was 0%. Non-target vessel revascularization and 
target vessel myocardial infarction (MI) were not reported. No cases of cardiac death or scaffold thrombosis were observed. Conclusion: BVS implantation in patients 






Coronary artery disease (CAD) is defined as myocardial ischemia as a result of irregularity between 
oxygen supply and needs in myocardium (less suply and/or more need). Obstructive coronary arteries are the 
most common reason (90-95%) and rarely some congenital anomalies, inflamation process, embolisation, 
systemis diseases (arteritis, systemic lupus erithematosus).
1
 Its epidemic character in last few decades is 
charecterised with high morbidity and mortality especially with high prevalence in developing countries, 
expectating to widespread in develop countries in 2020 year. According to World Health Organization it is 
leading cause for mortality all around the world among the people aged 60 and older. Patients with CAD have 
stenotic or occluded coronary arteries, resulting with chest pain, shortage of breath in rest or during exercise, 
electrocardiographic changes, heart attack or death.
2
 
CAD is characterized with variety of risk factors which can be defined as controlled and uncontrolled. 
Most common corelation is incidence of CAD with older age.
3,4
 But things are changing, moving towards 
younger population aged 45 and less exposed to higher risk for CAD especially in developing countries.
 5,6 
Acute coronary syndrome (ACS) is one of the most difficult clinical manifestation of CAD, continuing 
to be a major health problem, despite of impressive improvements in its diagnosis and therapy in last few 
decades. Because of the fact that a lot of population capable for working suffer from ACS, it is serious social 
and economy problem.
7
 Widespread use of aspirin and percutaneous coronary interventions (PCI) result in 
decreasing of morbidity and mortality of ACS.
8 
Percutaneous coronary intervention (PCI) is an optimal strategy to re-open the occluded or significantly 
narrowed coronary artery (culprit vessel) and improve the outcomes of patients with ACS.
9
 Access-site selection 
is an important procedural issue in PCI. Transradial approach (TRA) has been associated with lower rate of 
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access-site bleeding and vascular complications in comparison with transfemoral approach. This has been 
evident with the aggressive use of antithrombotic and antiplatelet therapy in patients with ACS.
10
 Vascular 
access-site complications have been shown to be associated with worse outcomes.
11 
Bioresorbable vascular scaffold (BVS) is interventional percutaneous device for treatment of coronary 
artery disease (Figure 1). It is covered with bioresorptive polymer and cytostatic drug which is eluted in the 
coronary artery wall in the period of 1-2 months, preventing the uncontrolled neointimal hyperplasia. BVS 
introduction is the 4-th revolution in percutaneous coronary interventions after introducing balloon angioplasty 
in 1977, bare metal stents in 1988 and drug eluting stents in 2001 year. 
 
Methods 
Study population. Patients with ACS scheduled for PCI and stenting regardless to indication were 
eligible to be included in this prospective study. The study is conducted in accordance with our local internal 
rewiew board regulations and written informed consent was obtained from all patients prior procedures. 
Intention to be treated are 100 consecutive patients with ACS.  
 Study protocol. Patients were divided in two groups: 
 Group 1 – consisting of 50 patients with ACS, with PCI through transradial approach and BVS 
implantation (Absorb Bioresorbable Vascular Scaffold System, Abbott Vascular);    
Group 2 - consisting of 50 patients with ACS, with PCI through transradial approach and second 
generation DES implantation. 
Vascular access. The radial atery was accessed after local infiltration with 1-1.5 ml 2% lidocaine, using 
puncture technique with a 20 G plastic intravenous cannula and 0.025‖ mini guidewire (45cm) and followed by 
5 Fr or 6 Fr hydrophilic introducer sheath (Terumo corporation) placement. Spasmolytic cocktail (5 mg 
verapamil) was given intraarterially through the radial sheath. 
Interventional procedures. Standard guide catheters were used to perform PCI (standard shapes like 
Judkins, EBU, Amplatz) mostly 6 Fr. Standard guidewires for PCI, mostly Balance Middle Weight (Abbott 
Vascular) were used according to case specifity. Manual thrombus aspiration was performed in cases with high 
thrombus burden. Stent choice was performed with sealed envelope randomization. 
Anticoagulation and antiplatelet treatments. Before PCI patients were treated with intravenous bolus 
of unfractionated heparin (100 IU/kg), aspirin (300 mg followed by 100 mg/day) and clopidogrel loading dose 
(600 mg followed by 75 mg/day for at least 1 year). After completion of PCI, weight-adjusted dosage protocol 
of heparin infusion was continued for 24 hours. 
Hemostasis management. The radial artery sheath was removed immediately after the procedure and 
hemostasis was achived by a simple bandage compression or TR band (Terumo Corporation). Simple bandage 
compression was applied with 4-6 small elastic bands, at the puncture site. The TR band was applied by inflating 
13-15 ml of air and after each hour the TR band was gradually deflated and totally removed after 4 hours. 
Patient has no mobility restriction after the procedure. 
Study endpoints. The primary endpoint  of the study was target lesion failure (TLF) at 30 days, 1 and 2 
years of follow up, defined as the composite of cardiovascular death, target vessel myocardial infarction (MI), or 
target vessel revascularization (TLR). The secondary endpoints were MI, TLR and definite stent thrombosis 
(ST) in both groups, comparing the survival rate between the patients in BVS and DES group.  
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Definitions. The criteria for TLF, MI and ST were consistent with the Academic Research Consortium 
(ARC). Target lesion failure was defined as the composite of cardiovascular death, target vessel myocardial 
infarction (MI), or target vessel revascularization (TLR). Cardiovascular death was defined as acute myocardial 
infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular 
procedures, death due to cardiovascular hemorrhage (intrapericardial bleed  with cardiac tamponade) or death 
due to other cardiovascular causes after the index procedure. Procedural success was determined by 
angiographic success, defined as the achievement of a minimum stenosis diameter reduction to <20% in the 
presence of grade 3 TIMI flow. Procedural time was calculated as the time needed from the local anesthesia 
injection until guide catheter removal.  
Control angiogram will be performed after 2 or 3 years from the index procedure to document the 
process of biodegradation of BVS with IVUS or OCT and measurements of minimal lumen diameter (MLD) of 
the vessel, minimal lumen area (MLA), minimal stent diameter (MSD) and minimal stent area (MSA). 
Statistical analysis. Data were expressed as mean +/- standard deviation for normally distributed 
numeric variables, or reported as median (min/max) when the data did not fit a normal distribution. Percentages 
were used to express categorical variables. Cathegorical variables were compared with chi-square test or 
Fisher’s exact test. Student’s t-test or Mann Whitney U-test were used to compare differences between two 
groups (continuous data) when appropriate.  
Acute coronary syndrome. ACS is caused by acute thrombosis induced by ruptured atherosclerotic 
plaque with or without vasoconstriction, resulting in sudden and critical reduction in blood flow.
12
 Because of 
the fact that this situation can be life threatening condition, the criterias for risk stratification are so perform that 
clinician can made decisions for patient treatment and to individualized them to every different patient. Main 
symptom is chest pain, but classification is based on electrocardiographic changes. There are two category of 
patients: 
 1) Patients with acute chest pain and ST segment elevation >20 min (STE-ACS) 
 2) Patients with acute chest pain and non ST segment elevation (NSTE-ACS) 
 
The incidencence of NSTE-ACS is higher and it is about 3 cases per 1000 population.
13,14
 In hospital 
mortality is higher in STE-ACS (7%) comparing to NSTE-ACS (3-5%), but after 6 months mortality rate is 
almost the same (12% comparing to 13%).
15,16
 Patients with NSTE-ACS are older, having more comorbidities, 
especially diabetes and renal failure. Epidemiology perception showed that treatment of NSTE-ACS should not 
be directed only to acute phase, but with the same intensity on long term period.
 17-23 
 
There are several diagnostic criteria for ACS: 





-electrocardiographic changes with ST segment depression > 1 mm (NSTEMI), transitory (less than 30 
minutes) ST segment elevation > 1mm in at least two contigues leads or ST segment elevation > 1mm in two 
standard leads or > 2mm in two conigues precordial leads (STEMI).
 29-31
 
-positive enzyme status – elevated cardiac markers in peiord for 24 hours, defined as elevated troponin 
T, troponin I, creatinin kinase (CK) and its cardiac isoenzyme (CK-MB) above the referent values. 
32-35
 
-coronary angiography, with coronary artery stenosis more than 70% or occlusion (‖culprit lesion‖). 
 
The recanalisation of culprit coronary artery is the basis of the ACS therapy. The first choise is 
mechanical recanalisation - percutaneous coronary intervention (PCI) through transradial approach (TRA) 
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because of the less bleeding comparing to transfemoral approach (TFA) and significanot lower mortality and 
major cardiac events. 
36-39 
 
Bioresorbable vascular scaffold. Bioresorbable vascular scaffold (BVS) – ABSORB (Abbott 
Vascular) is interventional percutaneous device for treatment of coronary artery disease. It is covered with 
bioresorptive polymer and cytostatic drug everolimus eluting in the coronary artery wall in the period of 1-2 
months, preventing the uncontrolled neointimal hyperplasia. It is 4-th revolution in percutaneous coronary 
interventions after introducing balloon angioplasty in 1977, bare metal stents in 1988 and drug eluting stents in 
2001 year.  
 
After BVS implantation the process of its resorption is starting through natural metabolic process in the 
period of 2-3 years and after that period the BVS is fully resorbed from the coronary artery (Figure 2). The 
bioresorption of the scaffold stops the mechanical pressure on the coronary artery, allowing the return of the 
vasomotoric function and the lumen of the vessel itself. It is very important to mention the fact that there is no 
more structure which is mechanically caging the coronary vessel and normal vasomotoric response to 








 clinical trials demonstrated excellent safety 
and efficacy. 
 
- The great advantage of this vascular reparative therapy appear during the return of the vasomotoric 
function of the coronary vessel itself and the resorptive phase and are visible after the first year of its 
implantation. With these advantages BVS enables life aquisitions for the patients which were not possible up to 
now in interventional cardiology. The revascularisation is equal to best in class second generation DES 
treatment in the first three months, but with BVS drug releasing and vessel caging are temporary and are present 
during the healing of the coronary vessel.   
- Expansion of the strategies for up to date treatment of the patients include widened use of invasive 
imaging techniques like intravascular ultrasound (IVUS), optical coherence tomography (OCT) and non invasive 
techniques like computerised tomography.
43 
- Extremely compatibility to the patients prone to allergic reactions with nickel and molibden which are 
releasing from the metalic stents and could be trigger mechanism for ―in stent‖ restenosis.
44,45 
 
It is very important to be emphasised that first implantations of BVS were limited to patients with stable 
angina, one vessel coronary artery disease, lesions type A, lesions without calcification. Today their use is safe 
and spread even in very complicated cases with left main stenosis, patients with ACS including acute myocardial 
infarction with ST segment elevation and present thrombotic burden (Figure 4), tortuous coronary arteries, 
diabetic patients.  
 
Results 
Until May 2015, 42 patients were enrolled in the stydy from the both groups. 
Group 1 – In this group 21 patients with ACS were enrolled with BVS implantation. Male patients 
were 66.7%,  female  33.3% of the patients. In 14 patients (66.7%) BVS was implanted on left anterior 
descending artery (LAD), in 4 patients (19.0%) on right coronary artery (RCA) and in 3 patients (14.3%) on 
circumflex artery (Cx).  Pre-procedural TIMI flow was 0 in 8 patients (38.1%), and TIMI  2-3 flow in 13 
patients (61.9%). After the BVS implantation TIMI 3 flow was achieved in all 21 patients. Post-procedural 
diameter stenosis was 16.7 +/- 8.9%. No patients had angiographically visible residual thrombus at the end of 
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the procedure. OCT analysis was performed in 13 patients (61.9%) showed that the post-procedure mean lumen 
area was 7.88 +/- 1.84 mm2, minimum lumen area 5.52 +/- 1.59 mm2.  
 
Group 2 – In this control group 21 patients with ACS were enrolled with second generation DES 
implantation. Male patients were 71.4%, female 28.6% of the patients. In 13 patients (61.9%) DES was 
implanted on left anterior descending artery (LAD), in 6 patients (28.6%) on right coronary artery (RCA) and in 
2 patients (9.5%) on circumflex artery (Cx).  Pre-procedural TIMI flow was 0 in 9 patients (42.9%), and TIMI  
2-3 flow in 12 patients (57.1%). After the DES implantation TIMI 3 flow was achieved in all 21 patients. Post-
procedural diameter stenosis was 15.4 +/- 8.2. No patients had angiographically visible residual thrombus at the 
end of the procedure. 
 
In all 42 patients, BVS and DES were successfully implanted without any complications, therefore 
device and procedural success were 100%. At the 30-day, 6-month (42 patients), 1 year (29 patients) and 2 years 
follow-up (16 patients) target-lesion failure rate was 0%. Non-target vessel revascularization, target vessel 
myocardial infarction (MI) or cerebrovascular insult were not reported. No episodes of cardiac death, scaffold or 




The present study is single centre report for first BVS implantation in Republic of Macedonia, 
investigating the safety and clinical outcomes of BVS in patients with acute coronary syndrome. 
  
Results of ABSORB Cohort A study report 5-year follow up at 29 patients with BVS implantation with 
major cardiovascular event (myocardial infarction without significant Q wave presence) at only one patient 
(3.4%). No episodes of cardiac death or scaffold thrombosis were observed.
40,41 
 
ABSORB Cohort B study report 2-year follow up at 100 patients with BVS implantation with major 
cardiovascular events in 9 patients (9.0%) (3 patients with non Q wave myocardial infarction and 6 patients with 
target lesion revascularisation). No episodes of cardiac death or scaffold thrombosis were observed.
 42 
 
ABSORB EXTEND study report 6-month follow up at 269 patients with BVS implantation with major 
cardiovascular events in 7 patients (3.0%) (4 patients with non Q wave myocardial infarction and 3 patients with 
Q wave myocardial infarction). The incidence of target lesion revascularisation was very low (0.4%), scaffold 
thrombosis in 1 patient (0.4%) cardiac death in 1 patient (0.4%).
43 
 
All three studies revealed excellent safety and efficacy. 
ABSORB II study which is the first randomized trial of the Absorb BVS (Abbott Vascular), enrolled 
501 patients, 335 patients (with 364 lesions) received bioresorbable scaffold and 166 patients (182 lesions) 
received the metallic stent. The one year follow up indicates that the scaffold has similar clinical outcomes to an 
everolimus-eluting metallic stent (Xience, Abbott Vascular) at one year. There were no significant differences 
between groups in either the rate of the device-oriented clinical endpoint between groups (5% for the 
bioresorbable scaffold vs. 3% for the metallic stent; p=0.35), or the rate of the patient-oriented clinical endpoint 
(7% vs. 9% respectively; p=0.47). Also one year angina rates were significantly lower with bioresorbable 
scaffold compared with the metallic stent: 22% vs. 30%, respectively (p=0.04). Nether the overall rate of 
definite stent thrombosis (0.6% for the bioresorbable scaffold vs. 0% for the metallic stent; p=1) nor the overall 
rate of definite/probable stent thrombosis (0.9% vs. 0%, respectively; p=0.55) was significantly different 
between groups; 
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The US ABSORB III trial with 2250 patients enrolled will provide more data.
46,47,48,49,50, 51 
Recent studies have investigated the clinical outcome of BVS in the setting of the novo coronary artery 
lesions, mostly limited to type A lesions in patients presenting with stable angina. Theoretical advantages of 
BVS over metal stents include the fact that the bioresorption of the scaffold allows the recovery of physiological 




It is important to emphasise that all interventions were performed through transradial approach, which 
lead to lower rate of bleeding events and consequently lower mortality rate.
 54, 55 
 
The results in our study correlate with already published results from several relevant multicenter trials 
with bioresorbable scaffolds, especially with ABSORB II study.
 
Our data apparently suggest that the outcome 
after the implantation of BVS is comparable to that of second generation drug-eluting stents. This study includes 
consecutive patients in a non-randomised design and further data are needed to provide a more definitive 
demonstration of safety and efficacy of this strategy. Despite this limitation, the present population is 




BVS implantation in patients presenting with ACS appeared feasible, it is safe and effective with high 
rate of final TIMI-flow III and good scaffold apposition and very low rate of major adverse cardiovascular 
events. Prudence and careful monitoring are essential in the adoption of a potentially revolutionary technique. 
Larger studies are currently needed to confirm these preliminary data. However, we cannot slowdown the 
progress of interventional cardiology while waiting for further megatrials. 
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